Related Experiment Video
Updated: Jun 25, 2026
08:46
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
53.3K
The method for assessing the specificity of developing CAR therapies
Ivan V Prikhodko1, Georgy Th Guria2
1Laboratory for Mathematical Modelling of Biological Processes, National Medical Research Center for Hematology, Moscow, Russia.
Biophysical Reports
|July 18, 2024
Summary
Chimeric antigen receptor (CAR) cell specificity is crucial for effective antitumor therapy. This study introduces CAR clustering as a key factor in assessing CAR cell specificity, moving beyond just sensitivity.
Area of Science:
- Immunotherapy
- Molecular Biology
- Biophysics
Background:
- Chimeric antigen receptor (CAR) therapy effectiveness relies on CAR cell sensitivity to target cells.
- CAR therapies face challenges with on-target, off-tumor toxicity due to nonspecific side effects.
- Current research prioritizes CAR cell sensitivity, often overlooking specificity.
Purpose of the Study:
- To propose a novel method for assessing CAR cell specificity.
- To investigate the role of CAR clustering in CAR cell cytotoxicity.
- To establish conditions for achieving both sensitivity and specificity in CAR therapies.
Main Methods:
- Utilizing nucleation theory to model CAR clustering.
- Deriving a master equation for CAR cell cytotoxicity probability.
- Analyzing the critical CAR cluster size as a key parameter.
Main Results:
- CAR clustering is identified as a determinant of CAR cell cytotoxicity.
- The size of a critical CAR cluster is a crucial parameter for specificity.
- Parametric diagrams are derived to explore conditions for sensitivity and specificity.
Conclusions:
- CAR clustering offers a new perspective for evaluating CAR cell specificity.
- This approach can aid in designing more specific and effective CAR therapies.
- The proposed method provides a framework for assessing CAR therapy specificity.
Related Concept Videos
01:25Mutagenicity and Carcinogenicity
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
01:26Therapeutic Drug Monitoring: Drug Analysis Methods
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...